MGI Pharma Inc.
5775 West Old Shakopee Road
Bloomington, MN 55437
Web Site: http://www.mgipharma.com
MGI PHARMA, INC., an oncology- and acute care- focused biopharmaceutical company, engages in the discovery, acquisition, development, and commercialization of proprietary pharmaceutical products. The company’s product portfolio includes, Aloxi (palonosetron hydrochloride) injection for the prevention of chemotherapy-induced nausea and vomiting; Salagen tablets (pilocarpine hydrochloride) for the symptoms of radiation-induced dry mouth in head and neck cancer patients, as well as symptoms of dry mouth associated with the autoimmune disease Sjögren’s syndrome; Hexalen (altretamine) capsules, which is an orally administered chemotherapeutic agent for ovarian cancer patients; Gliadel Wafer, a malignant glioma at time of initial surgery; and Aggrastat (tirofiban hydrochloride) injection for the treatment of acute coronary syndrome. The company’s products in various phases of clinical trials include Dacogen (decitabine) injection for the treatment of patients with myelodysplastic syndrome; Saforis oral suspension for chemotherapy induced inflammation of the tissues lining the mouth, or oral mucositis; Aquavan (fospropofol disodium) injection for sedation of patients undergoing diagnostic or surgical procedures; Aloxi (palonosetron hydrochloride) injection for the prevention of PONV; Aloxi Oral Capsule Formulation for the prevention of CINV; Amolimogene (HPV E6 E7 plasmid), which enhances the natural immune response of a patient infected with human papillomavirus; Irofulven for the treatment of prostate, liver, ovarian, and pancreatic tumors; and other acylfulvene analogs. MGI PHARMA markets its products through direct sales force within the United States and through alliances with other pharmaceutical or biotechnology companies in other countries. The company was incorporated in 1979 as Molecular Genetics, Inc. and changed its name to MGI PHARMA, Inc. in 1990. MGI PHARMA is headquartered in Bloomington, Minnesota.